TREX1 and Aicardi-Goutieres syndrome: Because of the role of L1 in AGS pathology, reverse transcriptase inhibitors (RTis) have been trialed in AGS patients and in vitro studies where they rescue neurotoxic phenotypes in TREX1-KO astrocytes [15, 53].